Adulterated and misbranded drugs, recalls, expiration, counterfeits, EUAs, importation, DSCSA
3 free Uniform MPJE practice questions on this topic, with the answer, a reason for every option and the source. The full bank has 85 questions here.
FDA inspects a drug manufacturer and finds that its manufacturing controls do not conform to current good manufacturing practice (cGMP), although every lot of the finished tablets passed release testing. Under the FD&C Act, the tablets are:
- Amisbranded, because the labeling implies cGMP compliance
- Badulterated, even though the finished lots meet their specifications
- Cnot in violation, because the finished lots meet their specifications
Show answer and sources
Answer: B. adulterated, even though the finished lots meet their specifications
Failure of manufacturing methods, facilities, or controls to conform to cGMP makes a drug adulterated (21 U.S.C. 351(a)(2)(B)), even if the finished product tests within specification.
- A. Incorrect: cGMP failure is an adulteration ground, not a misbranding ground.
- B. Correct: a drug made with methods, facilities, or controls that do not conform to cGMP is adulterated under 21 U.S.C. 351(a)(2)(B), regardless of final test results.
- C. Incorrect: passing release testing does not cure a cGMP failure; nonconformity alone makes the drug adulterated.
- [1] 21 U.S.C. §351 — Adulterated drugs . 21 U.S.C. 351(a)(2)(B)
A hospital pharmacy sends a sample of a USP-recognized injection for testing. The compendial assay shows the product contains 85% of the strength required by the USP standard, and its label does not mention any difference. Under the FD&C Act, the injection is:
- Aadulterated, because its strength differs from the compendial standard
- Bacceptable, because only a strength above the compendial standard is a violation
- Cacceptable, because the lot has not yet reached its expiration date
Show answer and sources
Answer: A. adulterated, because its strength differs from the compendial standard
A drug recognized in an official compendium is adulterated if its strength differs from, or its quality or purity falls below, the compendial standard (21 U.S.C. 351(b)).
- A. Correct: a compendial drug whose strength differs from the official standard, without a plain label statement of the difference, is adulterated under 21 U.S.C. 351(b).
- B. Incorrect: 351(b) covers any difference in strength, whether above or below the standard.
- C. Incorrect: an unexpired product is still adulterated if it fails the compendial strength standard.
- [1] 21 U.S.C. §351 — Adulterated drugs . 21 U.S.C. 351(b)
FDA investigators arrive at a pharmacy to inspect its compounding area. The owner refuses to let them enter. Under the FD&C Act, the drugs held at the pharmacy are:
- Adeemed adulterated because the owner refused the inspection
- Bdeemed misbranded because the owner refused the inspection
- Cunaffected, because refusal results only in a fine against the owner
Show answer and sources
Answer: A. deemed adulterated because the owner refused the inspection
A drug is adulterated if it was held in an establishment whose owner, operator, or agent delays, denies, or limits an FDA inspection or refuses entry (21 U.S.C. 351(j)); refusal is also a prohibited act under 331(f).
- A. Correct: drugs held in an establishment whose owner, operator, or agent delays, denies, limits, or refuses an FDA inspection are deemed adulterated (21 U.S.C. 351(j)).
- B. Incorrect: the statute places refusal of inspection under adulteration, not misbranding.
- C. Incorrect: refusal is also a prohibited act (331(f)), and 351(j) deems the drugs adulterated.
- [1] 21 U.S.C. §351 — Adulterated drugs . 21 U.S.C. 351(j)
- [2] 21 U.S.C. §331 — FDCA prohibited acts . 21 U.S.C. 331(f)
Practise all 85 questions on this topic
Tutor mode, timed blocks and progress tracking.